Skip to main content
Top
Published in: Pain and Therapy 3/2022

Open Access 14-06-2022 | Shingles | Letter

A Response to: Letter to the Editor Regarding “Determining the Definitive Time Criterion for Postherpetic Neuralgia Using Infrared Thermographic Imaging”

Authors: Woong Ki Han, HyunHee Cho, Francis Sahngun Nahm

Published in: Pain and Therapy | Issue 3/2022

Login to get access

Excerpt

Infrared thermographic image analysis showed that the transition of skin temperature from warm to cold occurs 12 weeks after herpes zoster onset (95% confidence interval 11–15 weeks, area under the receiver operating curve 0.901).
These findings serve as a theoretical basis for the timing definition of postherpetic neuralgia.
This is a response article to: Letter to the Editor Regarding “Determining the Definitive Time Criterion for Postherpetic Neuralgia Using Infrared Thermographic Imaging.”
Metadata
Title
A Response to: Letter to the Editor Regarding “Determining the Definitive Time Criterion for Postherpetic Neuralgia Using Infrared Thermographic Imaging”
Authors
Woong Ki Han
HyunHee Cho
Francis Sahngun Nahm
Publication date
14-06-2022
Publisher
Springer Healthcare
Keyword
Shingles
Published in
Pain and Therapy / Issue 3/2022
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-022-00399-5

Other articles of this Issue 3/2022

Pain and Therapy 3/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine